Reviewing Arcturus Therapeutics (ARCT) & Its Competitors

Arcturus Therapeutics (NASDAQ: ARCT) is one of 293 public companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its rivals? We will compare Arcturus Therapeutics to related companies based on the strength of its institutional ownership, risk, valuation, profitability, analyst recommendations, dividends and earnings.

Insider & Institutional Ownership

49.0% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 0.0% of Arcturus Therapeutics shares are held by company insiders. Comparatively, 17.4% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Arcturus Therapeutics and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Arcturus Therapeutics N/A -36.83% -34.70%
Arcturus Therapeutics Competitors -5,320.96% -107.55% -36.43%

Volatility and Risk

Arcturus Therapeutics has a beta of 1.44, indicating that its share price is 44% more volatile than the S&P 500. Comparatively, Arcturus Therapeutics’ rivals have a beta of 0.84, indicating that their average share price is 16% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations for Arcturus Therapeutics and its rivals, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Arcturus Therapeutics 0 3 3 0 2.50
Arcturus Therapeutics Competitors 1242 3627 12161 259 2.66

Arcturus Therapeutics currently has a consensus target price of $3.45, suggesting a potential downside of 35.75%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 46.84%. Given Arcturus Therapeutics’ rivals stronger consensus rating and higher possible upside, analysts plainly believe Arcturus Therapeutics has less favorable growth aspects than its rivals.

Valuation and Earnings

This table compares Arcturus Therapeutics and its rivals top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Arcturus Therapeutics N/A -$24.60 million -1.01
Arcturus Therapeutics Competitors $264.91 million $38.24 million 74.55

Arcturus Therapeutics’ rivals have higher revenue and earnings than Arcturus Therapeutics. Arcturus Therapeutics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Summary

Arcturus Therapeutics rivals beat Arcturus Therapeutics on 9 of the 13 factors compared.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Ltd, formerly Alcobra Ltd, is an Israel-based preclinical-stage biopharmaceutical company primarily focused on the discovery, development and commercialization of ribonucleic acid (RNA) medicines using lipid-mediated nanoparticle delivery system (LUNAR) and Unlocked Nucleomonomer Agent (UNA) Oligomer chemistry technology platforms. The Company, through Arcturus Therapeutics Inc, its wholly owned subsidiary based in the United States, is focused on developing RNA medicines for rare, infectious, fibrotic and respiratory diseases with unmet medical needs, including cystic fibrosis, nonalcoholic steatohepatitis (NASH) and rare liver diseases, as well as replicon RNA vaccines.

Receive News & Ratings for Arcturus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcturus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit